Xin Lang Cai Jing·2026-02-03 12:52Group 1 - Jichuan Pharmaceutical has announced the acquisition of exclusive commercialization rights for Kangfang Biotech's PCSK9 monoclonal antibody in mainland China, following a previous announcement regarding a JAK1/JAK2 inhibitor [2] - The company will pay a total of 80 million yuan (including tax) as an authorization fee and up to 10 million yuan (including tax) in milestone payments [4] - The PCSK9 monoclonal antibody, named Inusimab, is designed to specifically bind to PCSK9 and block its interaction with low-density lipoprotein receptors (LDL-R), thereby enhancing the clearance of low-density lipoprotein cholesterol (LDL-C) from the plasma [4] Group 2 - Inusimab is expected to be approved for market launch in September 2024, primarily for the treatment of primary hypercholesterolemia and mixed dyslipidemia, including heterozygous familial hypercholesterolemia (HeFH) and hypercholesterolemia in patients with atherosclerotic cardiovascular disease [4] - The drug will be included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List for 2025, officially implemented from January 1, 2026 [4]